Luminera Derm

Company Overview

Snapshot

Founded in February 2013, Luminera Derm operated with 11–50 employees, specializing in injectable medical devices. The company was acquired by Allergan Aesthetics in October 2020.

Business overview

Luminera Derm is an R&D company and manufacturer of injectable medical devices for aesthetic medicine. The company develops and produces a range of dermal fillers, including Crystalys, a calcium hydroxyapatite-based filler for facial volume restoration, and HArmonyCa, designed to promote natural collagen generation. Luminera Derm also offers Hydryalix, a cross-linked hyaluronic acid filler, and Hydryal, a non-cross-linked hyaluronic acid gel for skin hydration. All products adhere to ISO9001 and ISO13485 standards, serving the cosmetics, skin-care, and anti-aging markets across regions like Europe, Japan, and Israel.

Strategic signal

In October 2020, Luminera Derm was acquired by Allergan Aesthetics, an AbbVie company. This acquisition highlights the strategic value of Luminera Derm's injectable medical device portfolio within the aesthetic medicine market, signaling strong industry consolidation and a demand for advanced dermal filler technologies.

Company Intelligence Q&A

When was Luminera Derm acquired?

Luminera Derm was acquired in October 2020.

Which company acquired Luminera Derm?

Luminera Derm was acquired by Allergan Aesthetics, an AbbVie company.

What is Crystalys?

Crystalys is a calcium hydroxyapatite-based injectable dermal filler developed by Luminera Derm, designed to restore facial volume and natural contours by promoting natural collagen generation.

What is HArmonyCa?

HArmonyCa is an injectable product from Luminera Derm designed to restore facial volume and correct facial deficiencies by promoting the generation of natural endogenous collagen.

What quality standards do Luminera Derm products comply with?

All Luminera Derm products strictly comply with ISO9001 and ISO13485 standards.